ARWR · Arrowhead Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $8.26B |
| P/E | — |
| Float | 135.6M |
| Beta | 1.34 |
| Volatility | 33.6% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | High |
| Clavix score | 63.9 |
| Price | 56.06 |
| Change | +0.29% |
| Prev Close | 55.90 |
| Open | 58.50 |
| Day Low | 57.40 |
| Day High | 59.40 |
| Avg Vol | 2 |
| Avg $ Vol | $122.4M |
| 52W High | 95.49 |
| 52W Low | 34.61 |
| 52W Pos | 35.2% |
| From High | −41.29% |
| From Low | +61.98% |
| Max DD 1Y | −35.12% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −12.19% |
| SMA 50 | −26.39% |
| SMA 200 | −22.30% |
| RSI (14) | 27.6 |
| Vol 30D | 55.2% |
| Vol 90D | 56.0% |
| 1Y Range | 35–95 |
| Daily bars | 900 |
| Perf Week | −3.69% |
| Perf Month | −11.08% |
| Perf Quarter | −21.27% |
| Perf Half Y | −13.95% |
| Perf Year | +62.68% |
| Perf YTD | −17.30% |
| Prev Day | +0.29% |
| Clavix | C+ |
| Debt / Eq | 1.34 |
| Curr Ratio | 4.86 |
| Int Cover | -4.1× |
| FCF Margin | 18.9% |
| Rev Growth | +23258.2% |
| Profit | Unprofitable |
| Leverage | Moderate |
| Sector rank | 24 / 35 |
Clavix risk grade
regraded every trading dayARWR grades C+, 63.9 of 100. Steadiest on News Sentiment (65), most exposed on Price Stability (46, fragile). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 24 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ARWR | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.34 | 0.50 |
| Volatilityannualized | 33.6% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −35.1% | — |
| Typical daily movemedian absolute daily change | 1.89% | — |
| Days beyond ±3%of the last 252 sessions | 80 (32%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ARWR | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.34 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ARWR | |
|---|---|
| 1 week | −3.7% |
| 1 month | −11.1% |
| Year to date | −17.3% |
| 1 year | +62.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ARWR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 28 Aug |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 2 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ARWR | |
|---|---|
| Revenue growthyear over year | +23258.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openArrowhead Pharmaceuticals reported that its experimental drug ARO-MAPT cut levels of tau protein (a substance that builds up in the brains of people with Alzheimer's and related diseases) by up to 85% in spinal fluid during a small early-stage (phase 1) trial. The results validate the company's ability to deliver its gene-silencing drugs under the skin to the brain. The company plans to start two larger phase 2 trials of ARO-MAPT and move four additional brain-targeted drugs into human testing by the end of 2027.
Arrowhead Pharmaceuticals presented interim Phase I/II results showing its experimental RNA-based drug ARO-MAPT reduced tau protein levels in patients' cerebrospinal fluid by up to 73%, alongside early clinical data for its TRiM brain drug-delivery platform.
Arrowhead Pharmaceuticals announced interim Phase 1/2a clinical trial results for ARO-MAPT, its experimental RNA-based (RNAi) drug aimed at lowering tau protein in the brain for Alzheimer's disease and related disorders. The company reported deep and durable reductions of tau in healthy volunteers and said this is the first clinical proof that their platform can deliver siRNA across the blood-brain barrier and meaningfully turn down a target gene in the brain.
The FDA accepted ARWR's drug plozasiran into its STAR pilot program, a faster-track review process, for the company's upcoming application seeking approval to treat severe hypertriglyceridemia (dangerously high triglyceride levels that raise the risk of acute pancreatitis, a painful pancreas condition that often requires hospital care).
Arrowhead Pharmaceuticals announced that the FDA has accepted its drug plozasiran into the STAR pilot program, a fast-track-style review pathway, ahead of the company's upcoming application to also approve plozasiran for severe high triglycerides (a condition that raises the risk of dangerous pancreas episodes).
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TGTX | TG Therapeutics Inc | B- | $8.57B | 18.85 | 1.82 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $8.84B | 107.21 | 1.19 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.89B | — | 0.42 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.98B | 85.37 | 0.40 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.33B | — | 0.38 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.51B | — | 2.18 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.77B | 40.85 | 0.65 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.